Delivery Order SPE2DB22D2005-SPE2DB25FJQM5
Award Date 7/28/25
Potential Completion Date 8/18/25
Potential Value $17K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The Defense Logistics Agency awarded a $1,732.55 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with an ultimate completion date of August 11, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,744.80 on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL vials (5mL) to support federal medical procurement needs. The award is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 20, 2025, and is funded through the Defense Logistics Agency's Medical Supply Chain division. This contract represents...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for HYPERRAB 300 Unit/mL, a rabies immunoglobulin product, with a ceiling value of $18,711.54. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under a child contract...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $18,711.54 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HYPERRAB 300 Unit/ML (1 unit). This firm fixed-price delivery order, with completion scheduled for August 28, 2025, represents a competitive award with no set-aside designation. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion...
- The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vial (5ML) on July 25, 2025, with an ultimate completion date of August 15, 2025. This is a non-set-aside contract, competitively awarded to support federal medical procurement needs. The product will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office and primary distribution operations. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product commonly used for post-exposure prophylaxis. This firm fixed price delivery order, valued at $10,744.80, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 through December 2026. The contract was...
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- This delivery order, issued on August 1, 2025, awards AmerisourceBergen Drug Corp $4,851.14 for supply of HYPERRAB 300 units/ml under a firm fixed-price contract with an ultimate completion date of August 22, 2025. The contract, which is not set-aside and competitively awarded, is funded by the Defense Logistics Agency's Medical Supply Chain division and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for...